BioNTech Non Current Assets Total vs Net Receivables Analysis

0A3M Stock

USD 122.95 0.52 0.42%

BioNTech financial indicator trend analysis is way more than just evaluating BioNTech SE prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioNTech SE is a good investment. Please check the relationship between BioNTech Non Current Assets Total and its Net Receivables accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Non Current Assets Total vs Net Receivables

Non Current Assets Total vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioNTech SE Non Current Assets Total account and Net Receivables. At this time, the significance of the direction appears to have weak relationship.

The correlation between BioNTech's Non Current Assets Total and Net Receivables is 0.3. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Net Receivables in the same time period over historical financial statements of BioNTech SE, assuming nothing else is changed. The correlation between historical values of BioNTech's Non Current Assets Total and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of BioNTech SE are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Non Current Assets Total i.e., BioNTech's Non Current Assets Total and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.3

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Net Receivables

Most indicators from BioNTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Selling General Administrative is expected to rise to about 673.4 M this year, although the value of Tax Provision will most likely fall to about 279.5 M.

	2022	2023	2024	2025 (projected)
Gross Profit	12.8B	3.2B	3.7B	5.8B
Total Revenue	17.3B	3.8B	4.4B	7.5B

Gross Profit Total Revenue

BioNTech fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Inventory	Other Current Assets	Other Stockholder Equity	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Total Stockholder Equity	Cash	Non Current Assets Total	Non Currrent Assets Other	Good Will	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Total Liab	Net Invested Capital	Long Term Investments
Other Current Liab		0.88	0.44	0.7	0.51	0.39	0.32	0.99	0.83	0.47	0.66	0.63	0.58	0.69	0.59	0.55	0.37	0.27	0.14	0.23	0.42	0.16	0.33	0.84	0.55	0.14
Total Current Liabilities	0.88		0.67	0.91	0.81	0.7	0.65	0.9	0.99	0.77	0.84	0.88	0.78	0.89	0.85	0.83	0.71	0.6	0.48	0.55	0.66	0.49	0.65	0.99	0.83	0.48
Other Liab	0.44	0.67		0.62	0.62	0.54	0.38	0.52	0.7	0.53	0.34	0.62	0.26	0.5	0.62	0.61	0.54	0.47	0.43	0.44	0.47	0.43	0.66	0.68	0.61	0.43
Net Tangible Assets	0.7	0.91	0.62		0.97	0.92	0.85	0.72	0.93	0.95	0.92	0.99	0.82	0.98	0.99	0.98	0.9	0.87	0.78	0.83	0.83	0.78	0.75	0.94	0.98	0.78
Retained Earnings	0.51	0.81	0.62	0.97		0.96	0.91	0.55	0.84	0.98	0.87	0.99	0.77	0.94	1.0	1.0	0.97	0.93	0.86	0.89	0.84	0.86	0.76	0.85	1.0	0.86
Accounts Payable	0.39	0.7	0.54	0.92	0.96		0.92	0.41	0.74	0.97	0.85	0.93	0.75	0.91	0.95	0.96	0.93	0.99	0.95	0.98	0.88	0.95	0.83	0.76	0.96	0.95
Other Assets	0.32	0.65	0.38	0.85	0.91	0.92		0.33	0.69	0.97	0.88	0.89	0.8	0.89	0.9	0.91	0.95	0.91	0.84	0.87	0.84	0.83	0.7	0.7	0.91	0.83
Net Receivables	0.99	0.9	0.52	0.72	0.55	0.41	0.33		0.86	0.5	0.65	0.66	0.57	0.69	0.62	0.59	0.42	0.3	0.16	0.25	0.42	0.19	0.34	0.86	0.59	0.17
Inventory	0.83	0.99	0.7	0.93	0.84	0.74	0.69	0.86		0.81	0.86	0.9	0.81	0.91	0.88	0.86	0.75	0.66	0.54	0.61	0.7	0.55	0.72	1.0	0.86	0.54
Other Current Assets	0.47	0.77	0.53	0.95	0.98	0.97	0.97	0.5	0.81		0.9	0.97	0.81	0.95	0.98	0.99	0.98	0.94	0.87	0.9	0.87	0.86	0.75	0.82	0.99	0.87
Other Stockholder Equity	0.66	0.84	0.34	0.92	0.87	0.85	0.88	0.65	0.86	0.9		0.9	0.95	0.98	0.9	0.89	0.82	0.81	0.7	0.78	0.82	0.71	0.7	0.87	0.89	0.7
Total Current Assets	0.63	0.88	0.62	0.99	0.99	0.93	0.89	0.66	0.9	0.97	0.9		0.81	0.97	1.0	0.99	0.95	0.88	0.8	0.84	0.83	0.8	0.73	0.91	1.0	0.79
Common Stock	0.58	0.78	0.26	0.82	0.77	0.75	0.8	0.57	0.81	0.81	0.95	0.81		0.89	0.8	0.79	0.73	0.72	0.63	0.7	0.78	0.64	0.69	0.81	0.79	0.63
Property Plant Equipment	0.69	0.89	0.5	0.98	0.94	0.91	0.89	0.69	0.91	0.95	0.98	0.97	0.89		0.97	0.96	0.88	0.86	0.77	0.83	0.86	0.77	0.75	0.92	0.96	0.76
Total Assets	0.59	0.85	0.62	0.99	1.0	0.95	0.9	0.62	0.88	0.98	0.9	1.0	0.8	0.97		1.0	0.95	0.91	0.83	0.87	0.84	0.83	0.75	0.89	1.0	0.83
Total Stockholder Equity	0.55	0.83	0.61	0.98	1.0	0.96	0.91	0.59	0.86	0.99	0.89	0.99	0.79	0.96	1.0		0.97	0.92	0.85	0.88	0.85	0.85	0.75	0.87	1.0	0.85
Cash	0.37	0.71	0.54	0.9	0.97	0.93	0.95	0.42	0.75	0.98	0.82	0.95	0.73	0.88	0.95	0.97		0.91	0.84	0.86	0.8	0.82	0.67	0.75	0.96	0.83
Non Current Assets Total	0.27	0.6	0.47	0.87	0.93	0.99	0.91	0.3	0.66	0.94	0.81	0.88	0.72	0.86	0.91	0.92	0.91		0.98	0.99	0.86	0.98	0.82	0.68	0.92	0.98
Non Currrent Assets Other	0.14	0.48	0.43	0.78	0.86	0.95	0.84	0.16	0.54	0.87	0.7	0.8	0.63	0.77	0.83	0.85	0.84	0.98		0.99	0.81	1.0	0.81	0.56	0.85	1.0
Good Will	0.23	0.55	0.44	0.83	0.89	0.98	0.87	0.25	0.61	0.9	0.78	0.84	0.7	0.83	0.87	0.88	0.86	0.99	0.99		0.85	1.0	0.83	0.63	0.88	0.99
Common Stock Shares Outstanding	0.42	0.66	0.47	0.83	0.84	0.88	0.84	0.42	0.7	0.87	0.82	0.83	0.78	0.86	0.84	0.85	0.8	0.86	0.81	0.85		0.82	0.76	0.72	0.85	0.81
Short Term Investments	0.16	0.49	0.43	0.78	0.86	0.95	0.83	0.19	0.55	0.86	0.71	0.8	0.64	0.77	0.83	0.85	0.82	0.98	1.0	1.0	0.82		0.82	0.58	0.85	1.0
Non Current Liabilities Total	0.33	0.65	0.66	0.75	0.76	0.83	0.7	0.34	0.72	0.75	0.7	0.73	0.69	0.75	0.75	0.75	0.67	0.82	0.81	0.83	0.76	0.82		0.72	0.75	0.81
Total Liab	0.84	0.99	0.68	0.94	0.85	0.76	0.7	0.86	1.0	0.82	0.87	0.91	0.81	0.92	0.89	0.87	0.75	0.68	0.56	0.63	0.72	0.58	0.72		0.87	0.56
Net Invested Capital	0.55	0.83	0.61	0.98	1.0	0.96	0.91	0.59	0.86	0.99	0.89	1.0	0.79	0.96	1.0	1.0	0.96	0.92	0.85	0.88	0.85	0.85	0.75	0.87		0.85
Long Term Investments	0.14	0.48	0.43	0.78	0.86	0.95	0.83	0.17	0.54	0.87	0.7	0.79	0.63	0.76	0.83	0.85	0.83	0.98	1.0	0.99	0.81	1.0	0.81	0.56	0.85

Click cells to compare fundamentals

BioNTech Account Relationship Matchups

High Positive Relationship

Total Assets	+ 1.0	Retained Earnings
Total Stockholder Equity	+ 1.0	Retained Earnings
Net Invested Capital	+ 1.0	Retained Earnings
Total Liab	+ 1.0	Inventory
Total Assets	+ 1.0	Total Current Assets
Net Invested Capital	+ 1.0	Total Current Assets

High Negative Relationship

Not Found

BioNTech fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Other Current Liab	494.6M	3.2B	1.6B	540.3M	621.3M	964.9M
Total Current Liabilities	606M	3.5B	3.0B	2.1B	2.4B	1.5B
Other Liab	205.6M	97.1M	109.8M	283.9M	326.5M	200.3M
Net Tangible Assets	179.6M	406.5M	1.2B	11.7B	13.5B	14.1B
Retained Earnings	(409.6M)	9.9B	18.8B	19.8B	22.7B	23.9B
Accounts Payable	102.3M	160M	204.1M	354M	407.1M	427.5M
Other Assets	2.4M	168.2M	22.2M	249.2M	286.6M	300.9M
Net Receivables	166.4M	12.4B	7.1B	2.2B	2.5B	3.4B
Inventory	64.1M	502.5M	439.6M	357.7M	411.4M	217.8M
Other Current Assets	89M	113.4M	271.9M	280.9M	323.0M	339.2M
Other Stockholder Equity	318.6M	691.5M	1.5B	1.8B	2.0B	2.1B
Total Current Assets	1.7B	15.1B	21.9B	19.5B	22.5B	23.6B
Property Plant Equipment	116.0M	148.1M	326M	520.4M	598.5M	628.4M
Total Assets	2.3B	15.8B	23.3B	23.0B	26.5B	27.8B
Total Stockholder Equity	1.4B	11.9B	20.1B	20.2B	23.3B	24.4B
Cash	1.2B	1.7B	13.9B	11.7B	13.4B	14.1B
Non Current Assets Total	651.7M	758.5M	1.4B	3.5B	4.0B	4.2B
Non Currrent Assets Other	1.0M	800K	6.5M	83.4M	95.9M	100.7M
Good Will	53.7M	57.8M	61.2M	362.5M	416.9M	437.7M
Common Stock Shares Outstanding	241.5M	242.5M	243.2M	237.7M	273.4M	260.6M
Short Term Investments	137.2M	381.6M	189.4M	4.9B	5.6B	5.9B
Non Current Liabilities Total	340.8M	455.5M	272.9M	689.9M	793.4M	400.6M
Total Liab	946.8M	3.9B	3.2B	2.8B	3.2B	2.1B
Net Invested Capital	1.4B	12.2B	20.3B	20.5B	23.5B	24.7B
Capital Stock	232.3M	246.3M	246.3M	248.6M	285.9M	259.5M
Net Working Capital	1.1B	11.6B	19.0B	17.5B	20.1B	21.1B
Intangible Assets	109.8M	144.6M	158.5M	804.1M	924.7M	971.0M
Property Plant And Equipment Net	326.0M	520.4M	821.1M	971.6M	1.1B	613.2M
Property Plant And Equipment Gross	326.0M	594.6M	821.1M	1.2B	1.4B	686.9M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:

How To Invest In BioNTech

Details

Is BioNTech Stock a good investment?

Details

What is BioNTech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioNTech Non Current Assets Total vs Net Receivables Analysis

Non Current Assets Total vs Net Receivables

Non Current Assets Total vs Net Receivables Correlation Analysis

Correlation Coefficient

Non Current Assets Total

Net Receivables

BioNTech fundamental ratios Correlations

BioNTech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioNTech fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY